Exchange: NASDAQ·Updated 07:26 PM EST

MTVA News

News
all
press releases
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726PR NewswireCAMBRIDGE, Mass., Nov. 17, 2026 Encouraging Preliminary Safety and Tolerability...
PR Newswire
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726PR NewswireCAMBRIDGE, Mass., Nov. 17, 2026 Encouraging Preliminary Safety and Tolerability...
PR Newswire
More News
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek 2026 MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek 2026PR NewswireCAMBRIDGE, Mass., Nov. 16...
PR Newswire
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireCAMBRIDGE, Mass., Nov. 13, 2026 Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in...
PR Newswire
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.read more...
Benzinga
MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical TrialPR NewswireCAMBRIDGE, Mass., Nov. 12, 2026 Adding to...
PR Newswire
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026 MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026PR NewswireCAMBRIDGE, Mass., Nov. 9, 2026 CAMBRIDGE, Mass., Nov. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA),a clinical-stage biotechnology company...
PR Newswire
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim DataPR NewswireCAMBRIDGE, Mass., Nov. 5, 2026 DA-1726 Also Demonstrated...
PR Newswire
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026PR NewswireCAMBRIDGE, Mass., Oct. 28, 2026 CAMBRIDGE, Mass...
PR Newswire
(RTTNews) - MetaVia Inc. (MTVA), a clinical-stage biotechnology company, on Tuesday announced the appointment of Sarah Browne as Chief Medical Officer, effective October 12...
Nasdaq News: Markets
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical OfficerPR NewswireCAMBRIDGE, Mass., Oct. 13, 2026Brings Extensive Experience Leading Liver and...
PR Newswire

Advertisement|Remove ads.